Dissemin is shutting down on January 1st, 2025

Published in

SAGE Publications, Acta Radiologica, 6(46), p. 599-609, 2005

DOI: 10.1080/02841850510021652

Links

Tools

Export citation

Search in Google Scholar

Functional Magnetic Resonance Imaging at 3T as a Clinical Tool in Patients with Intracranial Tumors

Journal article published in 2005 by D. van Westen ORCID, G. Skagerberg, J. Olsrud, P. Fransson ORCID, E.-M. Larsson
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Purpose: To investigate the potential of functional magnetic resonance imaging (fMRI) at 3T as a clinical tool in the preoperative evaluation of patients with intracranial tumors. High magnetic field strength such as 3T is of benefit for fMRI because signal-to-noise ratio and sensitivity to susceptibility changes are field-strength-dependent. Material and Methods: Twenty patients with tumors close to eloquent sensorimotor or language areas were studied. Motor, sensory, and two language paradigms (word generation, rhyming) were used; their effectiveness was determined as the percentage of patients in whom the functional area of interest was activated. Activation maps were calculated and their quality rated as high, adequate, or insufficient. The influence of fMRI on the neurosurgical decision regarding operability, surgical approach, and extent of the resection, was assessed. Results: Paradigm effectiveness was 90% for motor and 95% for sensory stimulation, and varied from 79% to 95% for word generation and rhyming in combination. Ninety percent of the activation maps held high or adequate quality. fMRI proved useful: in the decision to operate (9 patients), in the surgical approach (13 patients), and in extent of the resection (12 patients). Conclusion: fMRI at 3T is a clinically applicable tool in the work-up of patients with intracranial tumors.